Sionna Therapeutics (SION) Accumulated Expenses (2024 - 2026)
Quarterly results put Accumulated Expenses at $6.3 million for Q1 2026, up 86.72% from a year ago — trailing twelve months through Mar 2026 was $6.3 million (up 86.72% YoY), and the annual figure for FY2025 was $9.7 million, up 18.45%.
Sionna Therapeutics has reported Accumulated Expenses over the past 3 years, most recently at $6.3 million for Q1 2026.
- Accumulated Expenses reached $6.3 million in Q1 2026 per SION's latest filing, down from $9.7 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $9.7 million in Q4 2025 and bottomed at $3.4 million in Q1 2025.
- Median Accumulated Expenses over the past 3 years was $6.6 million (2025), compared with a mean of $6.7 million.
- The largest annual shift saw Accumulated Expenses increased 18.45% in 2025 before it soared 86.72% in 2026.
- Over 3 years, Accumulated Expenses stood at $8.2 million in 2024, then rose by 18.45% to $9.7 million in 2025, then tumbled by 34.55% to $6.3 million in 2026.
- Business Quant data shows Accumulated Expenses for SION at $6.3 million in Q1 2026, $9.7 million in Q4 2025, and $6.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Sionna Therapeutics | 1.87 Bn | 1.87 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.33 Mn |
| Dec 31, 2025 | 9.67 Mn |
| Sep 30, 2025 | 6.93 Mn |
| Jun 30, 2025 | 5.47 Mn |
| Mar 31, 2025 | 3.39 Mn |
| Dec 31, 2024 | 8.16 Mn |